Krystal Biotech Stock Performance
| KRYS Stock | USD 190.40 8.11 4.45% |
The company secures a Beta (Market Risk) of 1.54, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Krystal Biotech will likely underperform. At this point, Krystal Biotech has a negative expected return of -0.0325%. Please make sure to verify Krystal Biotech's potential upside and day median price , to decide if Krystal Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Krystal Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Krystal Biotech is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 4.45 | Five Day Return 11.1 | Year To Date Return 52.37 | Ten Year Return 1.7 K | All Time Return 1.7 K |
1 | Disposition of 5109 shares by Suma Krishnan of Krystal Biotech at 170.3241 subject to Rule 16b-3 | 09/06/2024 |
2 | IMVT Stock Up on Upbeat Data From Graves Disease Study of Batoclimab | 09/09/2024 |
3 | SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324 | 09/27/2024 |
4 | PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo | 10/23/2024 |
5 | 100 Invested In This Stock 5 Years Ago Would Be Worth 400 Today | 10/30/2024 |
6 | Krystal Biotech, Inc. Beats Q3 Earnings and Revenue Estimates | 11/04/2024 |
7 | Krystal Biotech Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth and ... | 11/05/2024 |
8 | Krystal Biotech Q2 EPS Forecast Increased by William Blair | 11/07/2024 |
9 | Krystal Biotech Scores Relative Strength Rating Upgrade - Investors Business Daily | 11/11/2024 |
10 | FMR LLCs Strategic Acquisition of Krystal Biotech Inc Shares | 11/13/2024 |
11 | Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc | 11/15/2024 |
12 | Jennison Associates LLC Sells 110,333 Shares of Krystal Biotech, Inc. - MarketBeat | 11/21/2024 |
| Begin Period Cash Flow | 161.9 M |
Krystal |
Krystal Biotech Relative Risk vs. Return Landscape
If you would invest 19,822 in Krystal Biotech on August 27, 2024 and sell it today you would lose (782.00) from holding Krystal Biotech or give up 3.95% of portfolio value over 90 days. Krystal Biotech is currently does not generate positive expected returns and assumes 2.4985% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Krystal, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Krystal Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Krystal Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Krystal Biotech, and traders can use it to determine the average amount a Krystal Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.013
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KRYS |
Estimated Market Risk
| 2.5 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Krystal Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Krystal Biotech by adding Krystal Biotech to a well-diversified portfolio.
Krystal Biotech Fundamentals Growth
Krystal Stock prices reflect investors' perceptions of the future prospects and financial health of Krystal Biotech, and Krystal Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Krystal Stock performance.
| Return On Equity | 0.0638 | ||||
| Return On Asset | 0.0458 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 4.9 B | ||||
| Shares Outstanding | 28.76 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 6.18 X | ||||
| Price To Sales | 22.67 X | ||||
| Revenue | 50.7 M | ||||
| EBITDA | 17.9 M | ||||
| Net Income | 10.93 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 8.09 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.45 X | ||||
| Book Value Per Share | 30.80 X | ||||
| Cash Flow From Operations | (88.8 M) | ||||
| Earnings Per Share | 1.77 X | ||||
| Market Capitalization | 5.48 B | ||||
| Total Asset | 818.36 M | ||||
| Retained Earnings | (269.83 M) | ||||
| Working Capital | 554.82 M | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
About Krystal Biotech Performance
Assessing Krystal Biotech's fundamental ratios provides investors with valuable insights into Krystal Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Krystal Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 741.62 | 659.22 | |
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | (0.14) | (0.15) | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Things to note about Krystal Biotech performance evaluation
Checking the ongoing alerts about Krystal Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Krystal Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Krystal Biotech generated a negative expected return over the last 90 days | |
| Krystal Biotech currently holds about 425.56 M in cash with (88.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58. | |
| Krystal Biotech has a poor financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Jennison Associates LLC Sells 110,333 Shares of Krystal Biotech, Inc. - MarketBeat |
- Analyzing Krystal Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Krystal Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Krystal Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Krystal Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Krystal Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Krystal Biotech's stock. These opinions can provide insight into Krystal Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.